Delgocitinib - Japan Tobacco/LEO Pharma
Alternative Names: CORECTIM; JTE-052; JTE-052A; LEO 124249; LEO 124249 cream; LP-0133Latest Information Update: 10 May 2024
At a glance
- Originator Japan Tobacco
- Developer Japan Tobacco; LEO Pharma
- Class Anti-inflammatories; Antiallergics; Antipsoriatics; Azetidines; Nitriles; Pyrimidines; Pyrrolidines; Skin disorder therapies; Small molecules; Spiro compounds
- Mechanism of Action Janus kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Atopic dermatitis
- Preregistration Eczema
- Phase II Alopecia areata; Autoimmune disorders; Discoid lupus erythematosus; Hypersensitivity; Inverse psoriasis
Most Recent Events
- 03 May 2024 LEO Pharma announces intention to launch elgocitinib for Eczema in the EU in Q4 2024
- 09 Mar 2024 Efficacy and adverse events data from a phase III OLE DELTA-3 trial in Eczema released by LEO Pharma
- 08 Mar 2024 Pharmacokinetics data from a phase I trial in Eczema (In volunteers) presented at the American Academy of Dermatology Annual Meeting 2024 (AAD-2024)